The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Antibody Structure, Instability, and Formulation
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Lyophilization and development of solid protein pharmaceuticals
Wang, W. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00423-3 · Cited by 1,175
Self-citationInstability, stabilization, and formulation of liquid protein pharmaceuticals
Wang, W. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00152-0 · Cited by 1,064
Self-citationAntibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Challenges in the development of high protein concentration formulations
Shire, S. J., Shahrokh, Z., & Liu, J. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20079 · Cited by 882
Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice
Carpenter, J. F., Pikal, M. J., Chang, B. S., & Randolph, T. W. (1997) · Pharmaceutical Research · doi:10.1023/a:1012180707283 · Cited by 683
Challenges in the Development of High Protein Concentration Formulations
Shire, S. J., Shahrokh, Z., & Liu, J. (2010) · Current Trends in Monoclonal Antibody Development and Manufacturing · doi:10.1007/978-0-387-76643-0_9 · Cited by 657
Structure-Immunogenicity Relationships of Therapeutic Proteins
Hermeling, S., Crommelin, D. J. A., Schellekens, H., & Jiskoot, W. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000029275.41323.a6 · Cited by 617
Cleland, J. L., Powell, M., & Shire, S. J. (1993) · PubMed · Cited by 543
Tao, M. H., & Morrison, S. L. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.8.2595 · Cited by 530
Cited by
Extrinsic Fluorescent Dyes as Tools for Protein Characterization
Hawe, A., Sutter, M., & Jiskoot, W. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9516-9 · Cited by 1,199
Protein aggregation: Pathways, induction factors and analysis
Mahler, H.-C., Friess, W., Grauschopf, U., & Kiese, S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21566 · Cited by 901
Effects of glycosylation on the stability of protein pharmaceuticals
Solá, R. J., & Griebenow, K. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21504 · Cited by 646
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Huber, V., Camisaschi, C., Berzi, A., Ferro, S., Lugini, L., Triulzi, T., Tuccitto, A., Tagliabue, E., Castelli, C., & Rivoltini, L. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.001 · Cited by 595
The structural basis of antibody–antigen recognition
Sela-Culang, I., Kunik, V., & Ofran, Y. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00302 · Cited by 530
A practical note on the use of cytotoxicity assays
Weyermann, J., Lochmann, D., & Zimmer, A. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.09.018 · Cited by 525
Heterogeneity of Monoclonal Antibodies
Liu, H., Gaza-Bulseco, G., Faldu, D., Chumsae, C., & Sun, J. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21180 · Cited by 481
Aggregates in monoclonal antibody manufacturing processes
Vázquez‐Rey, M., & Lang, D. A. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23155 · Cited by 479
Therapeutic protein aggregation: mechanisms, design, and control
Roberts, C. J. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.05.005 · Cited by 455
Glycosylation of Therapeutic Proteins: An Effective Strategy to Optimize Efficacy
Solá, R. J., & Griebenow, K. (2010) · BioDrugs · doi:10.2165/11530550-000000000-00000 · Cited by 440
Yamada, K., Shibata, H., Suzuki, K., & Citterio, D. (2017) · Lab on a Chip · doi:10.1039/c6lc01577h · Cited by 437
Physicochemical Stability of Monoclonal Antibodies: A Review
Le Basle, Y., Chennell, P., Tokhadze, N., Astier, A., & Sautou, V. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.08.009 · Cited by 429
Khawli, L. A., Goswami, S., Hutchinson, R., Kwong, Z. W., Yang, J., Wang, X., Yao, Z., Sreedhara, A., Cano, T., Tesar, D. B., et al. (2010) · mAbs · doi:10.4161/mabs.2.6.13333 · Cited by 419
Shaken, Not Stirred: Mechanical Stress Testing of an IgG1 Antibody
Kiese, S., Papppenberger, A., Friess, W., & Mahler, H.-C. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21328 · Cited by 397
Higel, F., Seidl, A., Sörgel, F., & Friess, W. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.01.005 · Cited by 360
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Self-citationThe state-of-play and future of antibody therapeutics
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 322
Mass spectrometry for structural characterization of therapeutic antibodies
Zhang, Z., Pan, H., & Chen, X. (2009) · Mass Spectrometry Reviews · doi:10.1002/mas.20190 · Cited by 316
Principles, approaches, and challenges for predicting protein aggregation rates and shelf life
Weiss, W. F., Young, T. M., & Roberts, C. J. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21521 · Cited by 308
Kanai, S., Liu, J., Patapoff, T. W., & Shire, S. J. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21322 · Cited by 304
Huhn, C., Selman, M. H. J., Ruhaak, L. R., Deelder, A. M., & Wuhrer, M. (2009) · PROTEOMICS · doi:10.1002/pmic.200800715 · Cited by 301
Rathore, N., & Rajan, R. S. (2008) · Biotechnology Progress · doi:10.1021/bp070462h · Cited by 289
Protein aggregation, particle formation, characterization & rheology
Amin, S., Barnett, G. V., Pathak, J. A., Roberts, C. J., & Sarangapani, P. S. (2014) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2014.10.002 · Cited by 279
Manufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
Structural properties of monoclonal antibody aggregates induced by freeze–thawing and thermal stress
Hawe, A., Kasper, J. C., Friess, W., & Jiskoot, W. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.06.001 · Cited by 255
Drying Technologies for the Stability and Bioavailability of Biopharmaceuticals
Emami, F., Vatanara, A., Park, E. J., & Na, D. H. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030131 · Cited by 254
Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies
Wang, X., Das, T. K., Singh, S. K., & Kumar, S. (2009) · mAbs · doi:10.4161/mabs.1.3.8035 · Cited by 198
Self-citationabYsis: integrated antibody sequence and structure-management, analysis, and prediction
Swindells, M. B., Porter, C. T., Couch, M., Hurst, J., Abhinandan, K. R., Nielsen, J. H., Macindoe, G., Hetherington, J., & Martin, A. C. R. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.08.019 · Cited by 184
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
Self-citationJin, Y., Lin, Z., Xu, Q., Fu, C., Zhang, Z., Zhang, Q., Pritts, W. A., & Ge, Y. (2019) · mAbs · doi:10.1080/19420862.2018.1525253 · Cited by 68
Giorgetti, J., D’Atri, V., Canonge, J., Lechner, A., Guillarme, D., Colas, O., Wagner-Rousset, E., Beck, A., Leize-Wagner, E., & François, Y.-N. (2018) · Talanta · doi:10.1016/j.talanta.2017.09.083 · Cited by 65
McAvan, B. S., Bowsher, L. A., Powell, T., O’Hara, J. F., Spitali, M., Goodacre, R., & Doig, A. J. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c00627 · Cited by 61
Biacchi, M., Said, N., Beck, A., Leize-Wagner, E., & François, Y.-N. (2017) · Journal of Chromatography A · doi:10.1016/j.chroma.2017.02.064 · Cited by 41
Thermodynamic Stability and Flexibility Characteristics of Antibody Fragment Complexes
Li, T., Verma, D., Tracka, M., Casas-Finet, J., Livesay, D., & Jacobs, D. (2013) · Protein & Peptide Letters · doi:10.2174/09298665113209990051 · Cited by 13
Sakai, T., Mashima, T., Kobayashi, N., Ogata, H., Duan, L., Fujiki, R., Hengphasatporn, K., Uda, T., Shigeta, Y., Hifumi, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43443-4 · Cited by 9
Nanoplasmonic Avidity‐Based Detection and Quantification of IgG Aggregates
Tran, T., Martinsson, E., Vargas, S., Lundström, I., Mandenius, C.-F., & Aili, D. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03446 · Cited by 8
Metadata
- Authors
- Wang, W., Singh, S., Zeng, D. L., King, K., & Nema, S.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 96
- Issue
- 1
- Pages
- 1-26
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2073948759
- Cited by
- 941
- References
- 82
- FWCI
- 8.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.